NRSN (NeuroSense Therapeutics) Debt-to-Asset : 0.17 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NRSN NeuroSense Therapeutics Ltd NRSN
29 GF Score
Price $0.46
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics Debt-to-Asset?

NeuroSense Therapeutics NRSN -2.33% 29 Debt-to-Asset is 0.17 as of Dec. 2025. GuruFocus rates NRSN with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

NeuroSense Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.10 Mil. NeuroSense Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.07 Mil. NeuroSense Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2025 was $1.03 Mil. NeuroSense Therapeutics's debt to asset for the quarter that ended in Dec. 2025 was 0.17.

NeuroSense Therapeutics  (NAS:NRSN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

NeuroSense Therapeutics Debt-to-Asset Related Terms

NeuroSense Therapeutics Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics Debt-to-Asset Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial 0.00 0.03 0.05 0.02 0.17

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.02 0.02 0.00 0.17

NRSN vs CELU, GRDX, ZIVO: Debt-to-Asset Comparison

For the Biotechnology subindustry, NeuroSense Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroSense Therapeutics Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's Debt-to-Asset falls into.


NRSN
29GF Score
NeuroSense Therapeutics Ltd NRSN
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

NeuroSense Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.098 + 0.072) / 1.028
=0.17

NeuroSense Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.098 + 0.072) / 1.028
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.17 mean?
NeuroSense Therapeutics (NRSN) has a Debt-to-Asset of 0.17 as of Dec. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on NeuroSense Therapeutics and its competitors.
Is NeuroSense Therapeutics' Debt-to-Asset too high?
NeuroSense Therapeutics' current Debt-to-Asset is 0.17. Overall, NeuroSense Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' Debt-to-Asset compare to CELU and GRDX?
NeuroSense Therapeutics' Debt-to-Asset of 0.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current Debt-to-Asset is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current Debt-to-Asset of 0.17. The current Debt-to-Asset is 0.17. NeuroSense Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current Debt-to-Asset is 0.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges H1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
29GF Score

Get the complete analysis for NRSN

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.46
Price